

European Respiratory Society Annual Congress 2012

Abstract Number: 245

Publication Number: P2019

Abstract Group: 2.1. Acute Critical Care

Keyword 1: Airway management **Keyword 2:** Extrapulmonary impact **Keyword 3:** No keyword

Title: Does technology matter? One intensive care unit's experience

Mr. Russell 1562 Graham russell.graham@memorialhermann.org¹, Ms. Roberta 1563 Melton bobbie.melton@memorialhermann.org¹, Mr. Adam 1564 Mullaly adam.mullaly@memorialhermann.org¹, Mr. Stanley 1565 Rhone stanley.rhone@memorialhermann.org¹ and Dr. James 1566 Fink fink.jim@gmail.com². ¹ Respiratory Care and Pulmonary Diagnostics Services, Memorial Hermann - Texas Medical Center, Houston, TX, United States, 77030 and ² Division of Respiratory Therapy, Georgia State University, Atlanta, GA, United States .

Body: Background: Pneumatic nebulizers (PN) can add significant flow to the circuit and can harbor harmful pathogens.¹ Use of a PN with mechanical ventilation (MV) often results in incomplete nebulization with retrograde contamination from the patient. Vibrating mesh nebulizers (VMN) have a physical barrier between the aerosol pathway and the medication reservoir, reducing risk of contamination. We hypothesized VMN would provide more effective therapy and potentially reduce the risk of VAP. Method: The Neuroscience ICU Respiratory Therapists initiated a QI project, trialing a VMN (Aerogen, Galway, Ireland), locating one controller in each room to avoid cross-contamination issues as part of a VAP reduction strategy. All medicated aerosol was performed by VMN. Cumulative data was compiled for the 12 months prior. The new method (VMN) was used for 9 months, resuming the old method for an additional 60 day period (to act as an additional control) Results:

Table 1

	12 Months Prior (Old Method)	9 Months (New Method)	60 Days Post (Old Method - Control)
Average Ventilator Days	5.62	3.95	4.87
ICU Length of Stay	4.52	3.51* (p<0.05)	3.72
VAP Rate (1000 Vent Days)	4.05	3.87	3.83

Use of VMN resulted in a 15% drop in vent days, with a 19% increase during the 60 day return. LOS decreased by 28.7% during the study period. There was no statistically significant change in VAP rate, possibly due to the change in weighted value from the decreased vent days. Conclusions: VMN was

preferred by the therapists. In this instance, the advent of technology was felt to make a significant impact on patient care. Further study of the impact of choice of aerosol delivery device on patient outcome is indicated. ¹ Respir Care 2005;50(6):725-741.